Table 3.
Range | ICER Laser Trabeculoplasty | ICER Prostaglandin Analogues | |
---|---|---|---|
Effectiveness of PGAs | 0.5 | 16824/ QALY | (Dominated by LTP)^ |
0.75 | 16824/QALY | (Dominated by LTP)^ | |
1.0 | 16824* / QALY | 14179/ QALY | |
1.25 | 16824* / QALY | 9621/ QALY | |
1.5 | 16824* / QALY | 7266/ QALY | |
Effectiveness of LTP | 0.5 | (Dominated by no treatment)^ | 14179 / QALY |
0.75 | 583432*/ QALY | 14179/ QALY | |
1.0 | 16824*/ QALY | 14179 / QALY | |
1.25 | 7750/ QALY | (Dominated by LTP)^ | |
1.5 | 4750/ QALY | (Dominated by LTP)^ | |
Annual Cost of PGAs | $0 | 15928*/ QALY | 9665/ QALY |
$250 | 16607*/ QALY | 13085/ QALY | |
$500 | 17285*/ QALY | 16505/ QALY | |
$750 | 17964*/ QALY | 22950/ QALY | |
$1000 | 18643/ QALY | 30600/ QALY | |
Time Horizon (years) | 9 | 71893/ QALY | 158725/ QALY |
20 | 20603*/ QALY | 19846/ QALY | |
25 | 16824*/ QALY | 14179/ QALY | |
30 | 15291*/ QALY | 11873/ QALY | |
Age onset OAG | 40 | 14872*/ QALY | 12037/ QALY |
50 | 10513*/ QALY | 12587/ QALY | |
60 | 9853*/ QALY | 14179/ QALY | |
70 | 21547*/ QALY | 19536/ QALY | |
80 | 38383/ QALY | 40257/ QALY | |
Utility for Different Severities of OAG | 0.9 / 0.95 / 0.99† | 14376*/ QALY | 12334/ QALY |
Annual Rate of OAG Progression | 5% | 36839*/ QALY | 33720/ QALY |
10% | 16824*/ QALY | 14179 / QALY | |
15% | 10710*/ QALY | 8969 / QALY | |
Cost of side effects from LTP | $0 | 16748*/ QALY | 14179/ QALY |
$800 | 16809*/ QALY | 14179/ QALY | |
$1600 | 16870*/ QALY | 14179/ QALY | |
$2000 | 16900*/ QALY | 14179/ QALY | |
Utility of side effects from LTP | 0.50 | 17149*/ QALY | 14179/ QALY |
0.79 | 16768*/ QALY | 14179/ QALY | |
0.89 | 16645*/ QALY | 14179/ QALY | |
0.99 | 16523*/ QALY | 14179/ QALY | |
Proportion of LTP patients | 0% | 16535/QALY | 14179/QALY |
who develop side effects | 2.5% | 16824/QALY | 14179 /QALY |
LTP strategy is dominated by PGA by extended dominance (lower QALYs at a higher $/QALY)
Utilities for different severities of glaucoma: 0.9 for severe OAG, 0.95 for moderate OAG, 0.99 for mild OAG
A strategy is considered “dominated” if it is more costly and less effective than the alternative Gray shading indicates the more cost-effective treatment option
OAG = open-angle glaucoma; LTP = laser trabeculoplasty; QALY = quality-adjusted life year; PGA = prostaglandin analogues; ICER = incremental cost effectiveness ratio